OncoCyte Corp (OCX) Trading Up 8.9%
OncoCyte Corp (NYSE:OCX) was up 8.9% during trading on Wednesday . The company traded as high as $4.63 and last traded at $4.55, with a volume of 82,654 shares trading hands. The stock had previously closed at $4.18.
OCX has been the topic of several research analyst reports. Canaccord Genuity reiterated a “buy” rating on shares of OncoCyte Corp in a report on Wednesday, June 15th. Zacks Investment Research upgraded OncoCyte Corp from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Wednesday, August 17th. Finally, Benchmark Co. lifted their price objective on OncoCyte Corp from $7.50 to $8.00 and gave the stock a “speculative buy” rating in a report on Tuesday, June 7th.
The stock’s market cap is $117.24 million. The stock has a 50 day moving average of $4.01 and a 200-day moving average of $4.44.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/oncocyte-corp-ocx-trading-up-8-9.html
OncoCyte Corp (NYSE:OCX) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. On average, equities analysts anticipate that OncoCyte Corp will post $0.04 earnings per share for the current year.
About OncoCyte Corp
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with MarketBeat.com's FREE daily email newsletter.